New drug TALZENNA under safety watch for BRCA-Linked prostate cancer
NCT ID NCT06733337
First seen Oct 31, 2025 · Last updated May 12, 2026 · Updated 35 times
Summary
This study looks at the safety of the drug TALZENNA in men with a specific type of advanced prostate cancer that has a BRCA gene change and no longer responds to hormone therapy. Only one participant will be enrolled and followed for up to 12 months to track any side effects. The goal is to understand how safe TALZENNA is in this patient group.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PROSTATE CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Pfizer Japan
Tokyo, Japan
Conditions
Explore the condition pages connected to this study.